We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Informatics-Driven Drug Discovery Platform

By Biotechdaily staff writers
Posted on 12 Aug 2002
An integrated, informatics-driven drug discovery platform, based on proprietary advances in chemogenomics and bioinformatics, is designed to improve and accelerate drug candidate approval.

The platform provides an integrated view of both the target and compound components of drug attrition that allows rapid validation of targets and therapeutic approaches. More...
Included is a comprehensive database of drug-target-indications for all prior, safe medicines mapped to the human and model organism genomes. Detailed binding site mapping, analysis, and comparison and precomputed pharmacophores are applied. These are further linked to chemical synthesis and bioassay protocols.

Called PharmaCarta, the platform was launched by Inpharmatica Ltd. (London, UK; www.inpharmatica.co.uk), which will use the platform for in-house discovery programs and also offer it for use in collaborative programs with clients. The company also recently launched Biotech Biopendium, a proteome annotation resource for high throughput annotation for target prioritization, target mining, and microarray analysis.

"The launch of Biotech Biopendium opens up a new and exciting target audience for Inpharmatica, a strategy which we are confident will create even greater opportunities for both us and our customers going forward,” said Richard Lingard, director of business development at Inpharmatica.





Related Links:
Inpharmatica

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Automatic Hematology Analyzer
CF9600
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Hematology Consumables
Bioblood Devices
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Alzheimer’s pathology can start 15 to 20 years before symptoms, and validated tools that reach patients earlier help pave the way for earlier detection. (Image Credit: Adobe Stock)

Alzheimer’s Blood Test Becomes First FDA-Cleared Option for Adults as Young as 40

C2N Diagnostics’ PrecivityAD2 blood test was cleared by the U.S. Food and Drug Administration (FDA) on August 20, 2026, for adults as young as 40 who are experiencing signs of cognitive impairment, according... Read more

Pathology

view channel
Image: Adrenal gland tumor stained with hematoxylin and eosin (top) and CYP11B2 (bottom) (Photo courtesy of Christofer Juhlin)

Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism

Primary aldosteronism is a common but underdiagnosed cause of hypertension, in which excess aldosterone promotes salt retention and raises blood pressure. Identifying the dominant source of hormone overproduction... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.